The Gut Microbiome in Amyotrophic Lateral Sclerosis: Emerging Mechanisms and Therapeutic Potential - PubMed
5 hours ago
- #Gut-Brain Axis
- #Neuroinflammation
- #Microbiome Therapy
- Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder with rapid progression.
- The gut microbiome is identified as a potential modifier of ALS biology, influencing immune responses, metabolism, and therapeutic bioavailability.
- Animal studies show dysbiosis contributes to barrier dysfunction and immune activation, with beneficial metabolites like butyrate delaying disease progression.
- Human studies consistently report microbial imbalances and reduced diversity in ALS patients, though findings vary.
- The gut-brain axis explains how microbial products affect the central nervous system via endocrine, neural, and immune pathways.
- Microbiota changes may also contribute to non-motor symptoms, such as depression and gastrointestinal issues.
- Integrating microbiome research with host genomics and metabolomics could lead to precision medicine approaches for ALS.
- Targeting the microbiome may offer novel therapeutic potential to modify disease outcomes in ALS.